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Despite advances in diagnosis and
treatment, lung cancer remains the most
common cause of cancer death in the United
States and worldwide. Shifting the stage
distribution at diagnosis from advanced to
localized disease through lung cancer
screening (LCS) reduces both lung cancer–
specific and all-cause mortality, as
demonstrated by the results of the National
Lung Screening Trial (NLST) (1). LCS is a
complex intervention that requires effective
execution and coordination so that the
benefits of screening outweigh the potential
harms, including false-positive results and
complications of downstream invasive testing.
Because the real-world population eligible for
LCS is likely to be older and to have more
comorbidities than the participants enrolled in
the NLST (2), there exists reasonable concern
that patients undergoing LCS in the general
population may experience more frequent
complications. In this perspective, we
discuss the burden of false-positive results of
low-dose computed tomographic (LDCT)
imaging of the chest and the effect of age
and comorbidities on risk of procedural
complications. We also discuss recent data
on the complications and costs of invasive
diagnostic pulmonary/thoracic procedures
in the general population and how these
data may relate to decision-making in
regard to LCS and incidentally found
lung abnormalities. Finally, we address
systemic issues that likely contribute to the
complication rate and advocate for effective
communication within the patient/physician
community to facilitate appropriate
patient/procedure selection and risk–benefit
discussions across the diagnostic spectrum of
patients with potential lung cancer.
LCS has been shown to be effective in
reducing mortality by 20% with LDCT
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compared with chest radiography in high-
risk current and former smokers (1).
However, this was associated with a high
frequency of false-positive screening results
and a small but not insignificant risk of
complications related to downstream
invasive testing. In the NLST, a considerably
higher rate of positive screening results
(defined as a noncalcified nodule measuring
>4 mm in average diameter) was noted in
the LDCT group than in the radiography
group (T0 [first screen], 27.3% vs. 9.2%; T1
[second screen], 27.9% vs. 6.2%; and T2
[third screen], 16.8% vs. 5.0%), and 96%
of these participants did not have cancer
(1). Of the 6,369 patients with positive
LDCT results, 758 (11%) had invasive
diagnostic testing (percutaneous needle,
bronchoscopic, or surgical procedures). Of
the 758 procedures, 295 (38.9%) were
performed in patients with benign findings.
Thus, 4.6% of the 6,369 patients with a
positive LDCT result had an invasive
procedure for benign disease (3). A post hoc
analysis demonstrated that false-positive
results were higher in older,Medicare-eligible
(.65 yr old) patients, who were also more
likely to undergo invasive diagnostic testing
(2); however, the complication rate from
invasive procedures appeared to be similar in
both age group cohorts (4). This begs the
question, At what point is the mortality
benefit of screening outweighed by the
morbidity and mortality of invasive workup?
With increased use of CT for both
screening and diagnostic indications, the
incidence of pulmonary nodules is also
increasing. Approximately 9.1 million chest
CT scans were performed in the United
States in 2010, and that number continues to
rise annually (5). Twenty percent to 30%
(more than 2 million) of those scans will
have an incidental finding requiring
additional follow-up (6). As of 2015, only
4% of eligible patients in the United States
underwent LCS, but if the entire eligible
population—6.8 million people (7)—
underwent screening, an estimated 1.6
million would have false-positive screening
results (defined as any noncalcified nodule
measuring >4 mm, adenopathy, or pleural
effusion later attributed to a benign etiology)
(1). If one were to apply the Lung-RADS
(Lung CT Screening Reporting and Data
System) criteria for a positive screening
result, defined as solid nodules of 6 mm
or greater, the false-positive rate would
decrease to 12.8%, which still results in
nearly 1 million false-positive screening
results (8). Although the majority of nodules
requiring evaluation are incidentally
detected, as LCS use increases, so will the
number of CT-detected nodules and
invasive diagnostic procedures performed to
evaluate them. With an aging population, a
larger burden of those procedures will likely
be borne by older, less healthy patients with
the comorbid conditions found with tobacco
smoking and age, such as chronic
obstructive pulmonary disease (COPD).
Unfortunately, every invasive
diagnostic procedure carries a risk of
complications, and COPD appears to
increase that risk. Invasive procedures
performed for lung abnormalities fall into
three categories:
1. Needle based: either ultrasound-guided
or CT-guided transthoracic needle
aspiration;





lavage, and transbronchial brushings;
and
3. Surgery based: including thoracotomy,
thoracoscopy, and mediastinoscopy.
In a population-based analysis, transthoracic
needle aspiration was associated with an overall
16% complication rate, which was higher in
current smokers, patients aged 60–69 years,
and those with COPD (9). Bronchoscopic
procedures for peripheral lung lesions have
been associated with an overall complication
rate of around 2% (10). In one study,
the respiratory complication rates for
bronchoscopy were higher in patients with
COPD than in those patients without COPD
(22% vs. 6%) (11). Likewise, outcomes of
noncardiac thoracic surgery have been shown
to be worse in patients with COPD, and
patients with COPD are more likely to have
other comorbidities (12). Considering that the
NLST enrolled a highly selected, healthier
cohort than the general screening population,
and given that the study was conducted in
high-volume, highly specialized centers, the
ability to replicate the benefit/harm ratio of the
NLST in community settings has been debated.
In fact, new data suggest that the risk
of complications of invasive testing for
pulmonary abnormalities may be higher in
the general population than observed in the
NLST (13). A recent study by Huo and
colleagues estimated complications and
costs of invasive diagnostic testing due to
lung abnormalities on chest CT to be more
than double those reported in the NLST
(1, 13). The comparisons made with the
NLST risk significant misinterpretation
by suggesting that LCS itself, rather than
evaluation of CT-detected abnormalities, in
the general population results in higher rates
of complications and downstream costs.
However, the results of the study by
Huo and colleagues are not necessarily
generalizable to LCS. For example, their
study cohort included patients in the
same age range who underwent invasive
diagnostic procedures similar to those
performed in the NLST, but the procedures
were for symptomatic or incidentally
detected lung abnormalities; the clinical
condition or indication for the procedures
were not defined; and the patients may have
been less healthy than their counterparts in
the NLST. Therefore, the results should not
be interpreted to imply that real-world LCS
results in higher downstream complications
and costs; rather, they should be considered
as a global commentary on the medical
community’s limitations in managing
CT-detected lung abnormalities (be they
screen identified or incidental) across an
aging and diverse patient population with a
growing comorbidity burden. Such an
observation, then, highlights the need to
place significant importance on the process
of correct selection of both the appropriate
patient and procedure needed to best
establish a diagnosis while exposing the
patient to the least amount of harm.
The high rate of complications and
costs associated with invasive diagnostic
procedures in the general population
observed by Huo and colleagues (13), as well
as the increasing age and comorbidities
of the U.S. population, also emphasizes
the need for discussing potential harms
and costs with all patients who are
recommended to undergo diagnostic
pulmonary procedures for CT-detected
abnormalities. Pulmonary physicians must
strive to offer LCS and the ensuing
diagnostic procedures to those who would
benefit most (i.e., those patients in whom the
rising risk of lung cancer death outweighs
the harms of pursuing diagnosis) (2). In
addition, we must also be thoughtful and
diligent in the way we develop programs: not
only to screen for lung cancer but also to
manage incidentally and symptomatically
identified lung abnormalities.
Unfortunately, there remain




guideline-directed care and the real-world
medical experience. In 2014, Ost and
colleagues demonstrated that, across all
medical settings, only 21% of patients had
a diagnostic evaluation for lung cancer
consistent with guidelines, and smaller-
volume centers tended to provide less
guideline-consistent care than their high-
volume counterparts (14). There is also
an ever-growing body of literature
suggesting that lung cancer care in high-
volume programs or designated centers of
excellence leads to better outcomes. For
example, it has been suggested that general
pulmonologists were less likely than
interventional pulmonologists to perform
guideline-appropriate endobronchial
ultrasound staging (15). The surgical
literature also suggests that outcomes are
better when the surgeon performing the
procedure is specialized in thoracic
surgery and if the cancer care is delivered
in a high-volume versus low-volume
setting (15, 16). However, the vast
majority of the U.S. population obtains
care at low-volume centers, and the
demand for subspecialized care far
outstrips the supply.
The need for a comprehensive,
multidisciplinary approach to abnormalities
detected by chest CT remains critical to
optimizing and individualizing diagnostic
algorithms for each patient by minimizing
futile procedures, maximizing diagnostic yield,
and optimizing mortality benefit. Multiple
resources exist to aid providers and centers in
developing LCS programs andmanagement of
nodules detected on LDCT and include
evidence-based, protocol-driven algorithms,
such as the American College of Chest
Physicians (ACCP) clinical practice guidelines
for the diagnosis and management of lung
nodules, an official policy statement from the
American Thoracic Society (ATS)/ACCP on
components and implementation of LDCT
LCS programs, and the ATS/American Lung
Association LCS guide website (17–20).
However, the need remains for a clinical tool
to identify patients who will benefit the
most from invasive diagnostic procedures
while minimizing harms. Such a tool
would ideally include individualized patient
characteristics based on epidemiological
and genomic classifier data to create an
objective ratio of risk of lung cancer
death to risk of harm from procedural
complications, as well as provide an easy-to-
follow management protocol. Until
such a tool exists, a multidisciplinary
approach, combined with risk–benefit
discussions with the patient and family, can
facilitate the decision-making process to
individualize and optimize management
of CT-detected lung abnormalities and is
an essential component of the standard
of care. n
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